CPIX News and Press, Cumberland Pharmaceuticals Inc. From 11/08/22

Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q3 Non-GAAP EPS of $0.10. Revenue of $11.41M (+40.9% Y/Y). Shares +6% . For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.10, revenue of $11.41M

Cumberland Pharmaceuticals Reports 41% Revenue Growth PR Newswire Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn. , Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutic...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will re...

CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST PR Newswire NASHVILLE, Tenn. , Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in ...

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development ...

Cumberland Pharmaceuticals Reports 14% Revenue Growth PR Newswire Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn. , Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialt...

CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021 PR Newswire The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues N...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that it will ...

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS PR Newswire NASHVILLE, Tenn. , July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Mart...

The following slide deck was published by Cumberland Pharmaceuticals Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Cumberland Pharmaceuticals Inc. 2022 Q1 - Results - Earnings Call Presentation